Search Results - "Miesbach, Wolfgang A." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

by von Drygalski, Annette, Gomez, Esteban, Giermasz, Adam, Castaman, Giancarlo, Key, Nigel S., Lattimore, Susan U., Leebeek, Frank W. G., Miesbach, Wolfgang A., Recht, Michael, Gut, Robert, Dolmetsch, Ricardo, Monahan, Paul E., Le Quellec, Sandra, Pipe, Steven W.
Published in Blood advances (10.10.2023)

Get full text

Journal Article

Prospective evaluation of ADAMTS-13 and von Willebrand factor multimers in cardiac surgery

Prospective evaluation of ADAMTS-13 and von Willebrand factor multimers in cardiac surgery

by Reinecke, Imke R, Weber, Christian F, Budde, Ulrich, Seifried, Erhard, Miesbach, Wolfgang A
Published in Blood coagulation & fibrinolysis (01.12.2016)

Get more information

Journal Article

Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)

Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)

by Miesbach, Wolfgang A., Recht, Michael, Key, Nigel S., Sivamurthy, Krupa, Monahan, Paul E., Pipe, Steven W.
Published in Blood (15.11.2022)

Get full text

Journal Article

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

by Miesbach, Wolfgang A., Di Minno, Giovanni, Santagostino, Elena, Klamroth, Dr, Bayh, Inga, Soto, Amaryllis, Hermans, Cedric
Published in Blood (13.11.2019)

Get full text

Journal Article

Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

by Pipe, Steven W., Leebeek, Frank W.G., Recht, Michael, Key, Nigel S., Lattimore, Susan, Castaman, Giancarlo, Cooper, David, Verweij, Stephanie, Dolmetsch, Ricardo, Tarrant, Jacqueline, Li, Yanyan, Monahan, Paul E., Miesbach, Wolfgang A.
Published in Blood (15.11.2022)

Get full text

Journal Article

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

by Pipe, Steven W., Leebeek, Frank W.G., Recht, Michael, Key, Nigel S., Lattimore, Susan, Castaman, Giancarlo, Coppens, Michiel, Cooper, David, Gut, Robert, Slawka, Sergio, Verweij, Stephanie, Dolmetsch, Ricardo, Li, Yanyan, Monahan, Paul E., Miesbach, Wolfgang A.
Published in Blood (15.11.2022)

Get full text

Journal Article

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

by Dunn, Amy L., Dargaud, Yesim, Abajas, Yasmina L., Carcao, Manuel, Castaman, Giancarlo, Giermasz, Adam, Hermans, Cédric, Lewandowska, Magdalena D., Mahlangu, Johnny, Meeks, Shannon L., Miesbach, Wolfgang A., Recht, Michael, Salinas, Vanessa, Chrisentery-Singleton, Tammuella, Wang, Hongying, Mitchell, Ian S, Young, Guy
Published in Blood (15.11.2022)

Get full text

Journal Article

First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α

First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α

by Shapiro, Amy D, Konkle, Barbara A., Croteau, Stacy E., Miesbach, Wolfgang A., Hay, Charles Richard Morris, Kazmi, Rashid, Mihova, Marina, Rangarajan, Savita, Pasi, John
Published in Blood (05.11.2020)

Get full text

Journal Article

AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years

AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years

by Leebeek, Frank W.G., Meijer, Karina, Coppens, Michiel, Kampmann, Peter, Klamroth, Robert, Schutgens, Roger, Castaman, Giancarlo, Seifried, Erhard, Schwaeble, Joachim, Bönig, Halvard, Sawyer, Eileen K, Miesbach, Wolfgang A.
Published in Blood (05.11.2020)

Get full text

Journal Article

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial

by von Drygalski, Annette, Giermasz, Adam, Castaman, Giancarlo, Key, Nigel S., Lattimore, Susan U., Leebeek, Frank W.G., Miesbach, Wolfgang A., Recht, Michael, Gomez, Esteban, Gut, Robert, Pipe, Steven W.
Published in Blood (05.11.2020)

Get full text

Journal Article

Perception of Actual Factor Concentrates and Expectations Towards Future Treatment with New Long-Lasting Products - Results of a Survey Among Haemophilia Patients in Germany - Analysis of Open Questions

Perception of Actual Factor Concentrates and Expectations Towards Future Treatment with New Long-Lasting Products - Results of a Survey Among Haemophilia Patients in Germany - Analysis of Open Questions

by Kalnins, Werner, Miesbach, Wolfgang A., von Mackensen, Sylvia
Published in Blood (03.12.2015)

Get full text

Journal Article

Acquired Factor X Deficiency in Systemic Light Chain Amyloidosis: Factor X Recovery after Bleeding Complications, Splenectomy, Chemotherapy and Remission

Acquired Factor X Deficiency in Systemic Light Chain Amyloidosis: Factor X Recovery after Bleeding Complications, Splenectomy, Chemotherapy and Remission

by Toenges, Rosa, Steinmann, Juliane, Siegemund, Annelie, Serve, Hubert, Miesbach, Wolfgang A.
Published in Blood (08.12.2017)

Get full text

Journal Article

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

by Pipe, Steven W., Recht, Michael, Key, Nigel S., Leebeek, Frank W.G., Castaman, Giancarlo, Lattimore, Susan U., Van Der Valk, Paul, Peerlinck, Kathelijne, Coppens, Michiel, O'Connell, Niamh, Pasi, John, Kampmann, Peter, Meijer, Karina, von Drygalski, Annette, Young, Guy, Hermans, Cedric, Astermark, Jan, Klamroth, Robert, Lemons, Richard S., Visweshwar, Nathan, Crary, Shelley, Kazmi, Rashid, Symington, Emily, Escobar, Miguel A., Gomez, Esteban, Kruse-Jarres, Rebecca, Kotowski, Adam, Quon, Doris, Wang, Michael, Wheeler, Allison P., Sawyer, Eileen K, Verweij, Stephanie, Colletta, Valerie, Bajma, Naghmana, Gut, Robert, Miesbach, Wolfgang A.
Published in Blood (19.11.2020)

Get full text

Journal Article

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

by Holstein, Katharina, Smith, Andrea, Knöbl, Paul, Dobbelstein, Christiane, Miesbach, Wolfgang A., Spannagl, Michael, Heinz, Jürgen, Scholz, Ute, Eichler, Hermann, Huth-Kühne, Angela, Klamroth, Robert, Koch, Armin, Tiede, Andreas
Published in Blood (08.12.2017)

Get full text

Journal Article

Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

by Leebeek, Frank W.G., Meijer, K, Coppens, Michiel, Kampmann, Peter, Klamroth, R, Schutgens, Roger, Castaman, Giancarlo, Seifried, Erhard, Schwaeble, J, Bonig, Halvard, Sawyer, Eileen K, Miesbach, Wolfgang A.
Published in Blood (08.12.2017)

Get full text

Journal Article

Phase 1-2 Clinical Trial of a Recombinant AAV5 Vector Containing the Human FIX Gene in Patients with Severe or Moderately Severe Haemophilia B

Phase 1-2 Clinical Trial of a Recombinant AAV5 Vector Containing the Human FIX Gene in Patients with Severe or Moderately Severe Haemophilia B

by Miesbach, Wolfgang A., Meyer, Christian, Nijmeijer, Bart, Salmon, Florence, Grosios, Nadina, Petry, Harald, Leebeek, Frank W.G.
Published in Blood (06.12.2014)

Get full text

Journal Article

Long-Term Investigation on Age-Dependent Variations of Coagulation Factors in Patients with Von Willebrand Disease and Hemophilia

Long-Term Investigation on Age-Dependent Variations of Coagulation Factors in Patients with Von Willebrand Disease and Hemophilia

by Miesbach, Wolfgang A., Delbrueck, Christine, Krekeler, Stefanie, Alesci, Sonja
Published in Blood (18.11.2011)

Get full text

Journal Article

Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy

Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy

by von Drygalski, Annette, Gomez, Esteban, Giermasz, Adam, Castaman, Giancarlo, Key, Nigel S, Lattimore, Susan S, Leebeek, Frank W G, Miesbach, Wolfgang A, Recht, Michael, Gut, Robert Z, Dolmetsch, Ricardo, Monahan, Paul E, Le Quellec, Sandra, Pipe, Steven W
Published in Blood advances (09.12.2022)

Get full text

Journal Article

Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B

Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B

by Leebeek, Frank W.G., Tangelder, Marco, Meijer, Karina, Castaman, Giancarlo, Cattaneo, Federica, Coppens, Michiel, Kampmann, Peter, Klamroth, Robert, Schutgens, Roger E.G., Seifried, Erhard, Schwaeble, Joachim, Boenig, Halvard, Hendriks, Maaike, Corzo, Deya, Miesbach, Wolfgang A.
Published in Blood (02.12.2016)

Get full text

Journal Article

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand’s Disease in an Open-Label, Prospective, Non-Interventional Study (wilate®-SET)

Descriptive Evaluation of Age-Related Differences in Clinical Manifestation and Treatment of Von Willebrand’s Disease in an Open-Label, Prospective, Non-Interventional Study (wilate®-SET)

by Hegener, Oliver, Scharrer, Inge, Feddern, Jennifer, V, Wolfgang A. Miesbach, Von Depka, Mario, Kadar, Janos
Published in Blood (16.11.2012)

Get full text

Journal Article